Indication

For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Medicine details

Medicine name:
secukinumab (Cosentyx)
SMC ID:
SMC2308
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
11 January 2021
SMC meeting date:
01 December 2020
Patient group submission deadline:
02 November 2020